Compare · BLCO vs STAA
BLCO vs STAA
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- BLCO is the larger of the two at $5.51B, about 3.7x STAA ($1.49B).
- Over the past year, BLCO is up 29.4% and STAA is up 74.9% - STAA leads by 45.5 points.
- BLCO has been more active in the news (16 items in the past 4 weeks vs 4 for STAA).
- STAA has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Bausch + Lomb Corporation
- STAAR Surgical Company
- Price
- $15.48+0.72%
- $30.02+0.50%
- Market cap
- $5.51B
- $1.49B
- 1M return
- -3.25%
- +8.14%
- 1Y return
- +29.43%
- +74.94%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 16
- 4
- Recent ratings
- 18
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest BLCO
- SEC Form SD filed by Bausch + Lomb Corporation
- Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
- Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)
- Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)
- Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)
- Director Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)
- Director Ling Karen was granted 15,842 shares, increasing direct ownership by 35% to 61,518 units (SEC Form 4)
- Director Kavanagh Sarah B was granted 15,842 shares, increasing direct ownership by 30% to 69,541 units (SEC Form 4)
- Director Collis Steven H was granted 15,842 shares, increasing direct ownership by 61% to 42,003 units (SEC Form 4)
- Director Bernier Nathalie D. was granted 15,842 shares, increasing direct ownership by 23% to 85,505 units (SEC Form 4)
Latest STAA
- STAAR Surgical Announces Participation in Upcoming Investor Conferences
- Chief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)
- Interim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)
- STAAR Surgical upgraded by Wedbush with a new price target
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 3,448 shares, decreasing direct ownership by 5% to 66,917 units (SEC Form 4)
- Chief Development Officer Michna Magda covered exercise/tax liability with 1,680 shares, decreasing direct ownership by 5% to 32,691 units (SEC Form 4)